ABIVAX vs Caris Life Sciences

ABIVAX (ABVX), health care, and Caris Life Sciences (CAI), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

ABIVAX is worth $7.2B on the stock market and Caris Life Sciences $5.7B: ABIVAX is valued at 26% more. Over the past year ABIVAX's share price has moved -26.5% and Caris Life Sciences's -11.6%.

Key facts

ABIVAX market value
$7.2B
Caris Life Sciences market value
$5.7B
Caris Life Sciences P/E
12.0
Caris Life Sciences revenue
$812MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

ABIVAX vs Caris Life Sciences: every measure side by side
Measure ABIVAX Caris Life Sciences
SectorHealth CareHealth Care
Country France United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.2Bhigher$5.7Blower
Revenue—$812M
Earnings-$372.9Mlower-$68.1Mhigher
Employees98lower1,846higher
Total assets$648.3Mlower$1.1Bhigher
Valuation
P/E—12.0
P/S—7.0
P/B—8.9
Dividend yield—0.00%
Profitability
Operating margin—5.56%
Balance sheet
Net assets$505.1Mlower$577.3Mhigher
Total liabilities$143.3Mlower$548.4Mhigher
Total debt—$379M
Cash on hand$573.3Mlower$796.3Mhigher
Price change
Today-1.81%higher-5.05%lower
1 year-26.5%lower-11.6%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Caris Life Sciences only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns ABVX · Who owns CAI

Further comparisons

Learn

Questions and answers

Which is bigger, ABIVAX or Caris Life Sciences?

By market value, ABIVAX is the larger: $7.2B against $5.7B for Caris Life Sciences.

Which superinvestors own both ABIVAX and Caris Life Sciences?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold ABIVAX and 2 hold Caris Life Sciences.

Cite this page

Funkfolio, “ABIVAX vs Caris Life Sciences”, data as of 18 November 2026. https://funkfolio.com/compare/abvx-vs-cai

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.